Oxford Biomedica plc (LON:OXB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Oxford Biomedica plc (LON:OXB) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is GBX 604.32.

Several equities research analysts recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 1,170 target price on shares of Oxford Biomedica in a report on Wednesday, June 3rd. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 950 price objective on shares of Oxford Biomedica in a research note on Wednesday, March 11th.

Oxford Biomedica Stock Performance

Shares of LON:OXB opened at GBX 609 on Friday. The company has a market cap of £736.94 million, a P/E ratio of -22.62 and a beta of 1.10. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. Oxford Biomedica has a one year low of GBX 305.50 and a one year high of GBX 952. The business’s 50-day simple moving average is GBX 612.91 and its 200 day simple moving average is GBX 663.51.

Oxford Biomedica (LON:OXB) last announced its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. On average, sell-side analysts forecast that Oxford Biomedica will post -31.0799998 earnings per share for the current fiscal year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.